Egyszerű nézet

dc.contributor.author Catalano S
dc.contributor.author Campana A
dc.contributor.author Giordano C
dc.contributor.author Győrffy, Balázs
dc.contributor.author Tarallo R
dc.contributor.author Rinaldi A
dc.contributor.author Bruno G
dc.contributor.author Ferraro A
dc.contributor.author Romeo F
dc.contributor.author Lanzino M
dc.contributor.author Naro F
dc.contributor.author Bonofiglio D
dc.contributor.author Andò S
dc.contributor.author Barone I
dc.date.accessioned 2017-06-19T08:11:11Z
dc.date.available 2017-06-19T08:11:11Z
dc.date.issued 2016
dc.identifier 84969248061
dc.identifier.citation pagination=2271-2282; journalVolume=22; journalIssueNumber=9; journalTitle=CCR CLINICAL CANCER RESEARCH;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/4277
dc.identifier.uri doi:10.1158/1078-0432.CCR-15-1900
dc.description.abstract Purpose: By catalyzing cGMP hydrolysis, phosphodiesterase (PDE) 5 is a critical regulator of its concentration and effects in different (patho)physiologic processes, including cancers. As PDE5 is a known druggable target, we investigated the clinical significance of its expression in breast cancer and the underlying mechanisms by which it may contribute to tumor progression. Experimental Design: PDE5 expression was evaluated in seven breast cancer cell lines by RT-PCR and immunoblotting. To examine the impact of PDE5 on cancer phenotype, MCF-7 cells expressing lower levels of the enzyme were engineered to stably overexpress PDE5. Proliferation was evaluated by MTT assays, motility and invasion by wound-healing/transmigration/invasion assays, transcriptome-profiling by RNA-sequencing, and Rho GTPase signaling activation by GST-pulldown assays and immunoblotting. Clinical relevance was investigated by IHC on tissues and retrospective studies from METABRIC cohort. Results: PDE5 is differentially expressed in each molecular subtype of both breast cancer cell lines and tissues, with higher levels representing a startling feature of HER2-positive and triplenegative breast cancers. A positive correlation was established between elevated PDE5 levels and cancers of high histologic grade. Higher PDE5 expression correlated with shorter patient survival in retrospective analyses. On molecular level, stable PDE5 overexpression in Luminal-A-like MCF-7 cells resulted in enhanced motility and invasion through Rho GTPase signaling activation. Treatment of PDE5-stable clones with selective ROCK or PDE5 inhibitors completely restored the less motile and weak invasive behavior of control vector cells. Conclusions: PDE5 expression enhances breast cancer cell invasive potential, highlighting this enzyme as a novel prognostic candidate and an attractive target for future therapy in breast cancers. © 2015 AACR.
dc.relation.ispartof urn:issn:1078-0432
dc.title Expression and function of phosphodiesterase type 5 in human breast cancer cell lines and tissues: Implications for targeted therapy
dc.type Journal Article
dc.date.updated 2017-04-05T12:23:59Z
dc.language.rfc3066 en
dc.identifier.mtmt 3076313
dc.identifier.wos 000375329100023
dc.identifier.pubmed 26667489
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet